According to a new report, published by KBV research, The Global Rare Diseases Treatment Market size is expected to reach $255.4 billion by 2028, rising at a market growth of 12.5% CAGR during the forecast period.
The Biologics market is leading the Global Rare Diseases Treatment Market by Drug Type in 2021, thereby, achieving a market value of $141 billion by 2028. Biotechnology as well as research techniques advancements have aided in the development of novel biologics. The high target significance and the possibility of biological drugs revolutionizing the treatment of certain rare diseases will drive the market growth.
The Hospital Pharmacy market is exhibiting a CAGR of 12.7% during (2022 - 2028). This is due to the high hospitalization rate of SMA. Because of the high risk of breathing issues and scoliosis, the majority of people are treated in hospitals. Also, the hospitals are now enhancing their healthcare facilities in order to better serve the people.
The Injectable market has high growth rate in Global Rare Diseases Treatment Market by Route of Administration in 2021, thereby, achieving a market value of $144.25 billion by 2028. This is due to the introduction of novel injectables for the treatment of rare diseases. In addition, the demand for the rare disease injectables would increase as a result of the benefit that these are directly injected in the nerves.
The Cardiovascular Conditions market is poised to grow at a CAGR of 11.4% during (2022 - 2028). Despite their low prevalence, rare cardiovascular diseases pose a serious threat to public health and significantly lower the quality of life for those who are affected and their families. Regarding the type & complexity of the diseases, and their clinical manifestations, the population of adults with RDs exhibits significant heterogeneity.
The North America market is leading the Global Rare Diseases Treatment Market by Region in 2021, thereby, achieving a market value of $90.7 billion by 2028. The Europe market is expected to witness a CAGR of 12% during (2022 - 2028). Additionally, The Asia Pacific market is expected to witness a CAGR of 12.9% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/rare-diseases-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
By Drug Type
By Distribution Channel
By Route of Administration
By Therapeutic Area
By Geography
Companies Profiled
Unique Offerings 
